Discussing the complex and sometimes conflicting relationships between omega-6 polyunsaturated fatty acids (PUFAs), particularly linoleic acid (LA), and cardiometabolic health outcomes such as Type 2 Diabetes (T2D) and Cardiovascular Disease (CVD). One study, utilizing bidirectional Mendelian randomization (MR), suggests that high LA levels may reduce the risk of T2D and improve glycemic traits, while T2D itself appears to reduce LA levels. Conversely, several systematic reviews and meta-analyses of randomized controlled trials (RCTs) highlight that replacing saturated fat with LA-rich oils lowers LDL cholesterol but often fails to translate into a significant reduction in major coronary heart disease events or overall mortality, which critics call the "Linoleic Acid Paradox." Historical data from the 20th century further contextualizes these issues, showing a massive increase in LA consumption, largely from soybean oil, which may have negatively impacted protective omega-3 tissue concentrations. Concerns are also raised about the molecular toxicology of LA, particularly when sourced from refined and thermally abused oils, suggesting that oxidative products may negate LA's metabolic benefits.